IP Library Granted Patent US 10,259,826
Granted Patent B2
US 10,259,826 · App. 15/468,467 · Granted Apr 16, 2019

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Inventors: Rajinder Singh (Belmont, CA); Ankush Argade (Foster City, CA); Hui Li (Santa Clara, CA); Somasekhar Bhamidipati (Foster City, CA); David Carroll (San Francisco, CA); Catherine Sylvain (San Mateo, CA); Jeffrey Clough (Redwood City, CA); Holger Keim (Irvine, CA)
Assignee: RIGEL PHARMACEUTICALS, INC.
C07D498/04A61K31/506A61K31/538A61K31/541A61P19/02C07D403/12C07D403/14C07D405/12C07D405/14C07D413/12C07D413/14C07D417/12C07D417/14C07D498/02C07D498/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,259,826
App. No.
15/468,467
Granted
Apr 16, 2019
Kind
B2
Abstract

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Claims (7)

1. A compound that is (R)-5-Fluoro-N2-(1-methylindazol-6-yl)-N4-(2-methyl-3-oxo-2H,4H-benz[1,4]oxazin-6-yl)-2,4-pyrimidinediamine or a pharmaceutically acceptable salt thereof.

2. A method of inhibiting IgE-induced degranulation of immune cells, the method comprising contacting the cells with a compound according to claim 1 .

3. A method of inhibiting Syk kinase in a cell, the method comprising contacting the cell with a compound according to claim 1 .

4. A method of treating rheumatoid arthritis in a subject in need of such treatment, the method comprising administering an effective amount of a compound according to claim 1 to the subject.

5. The method of claim 2 , wherein the cell is in a human.

6. The method of claim 3 , wherein the cell is in a human.

7. The method of claim 4 , wherein the subject is a human.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2017
From: SINGH, RAJINDER; ARGADE, ANKUSH; LI, HUI; BHAMIDIPATI, SOMASEKHAR; CARROLL, DAVID; SYLVAIN, CATHERINE; CLOUGH, JEFFREY; KEIM, HOLGER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 041729/0369 →
Continuity (6)
Continuation 13442480 · Apr 9, 2012
Continuation 10903263 · Jul 30, 2004
Provisional Application 60491641 · Jul 30, 2003
Provisional Application 60531598 · Dec 19, 2003
Provisional Application 60572246 · May 18, 2004
Related Publication 20180072756A1 · Mar 15, 2018
Cited By (2)
US 12,377,097 US 12,479,833